Introduction
The TCF-4 gene codes for a transcription factor involved in the Wnt/Wingless signalling pathway and plays a crucial role in many developmental processes as well as in human carcinogenesis (Clevers and van de Wetering, 1997) . It is the most intensively expressed member of the TCF/LEF gene family in normal colonic tissue. Gene disruption of the murine germ line in TCF-4À/À -deficient mice has revealed that this transcription factor is required to establish the proliferative progenitors of prospective crypts in the intestine during embryonic development (Korinek et al., 1998) . Transcriptionally inert TCF factors become potent transactivators upon interaction with b-catenin (Behrens et al., 1996; Korinek et al., 1997) . The binding of TCF-4 protein to b-catenin is required to activate the Wnt/ Wingless pathway in colon tissue. b-Catenin/TCF-4 complexes regulate the transcription of many target genes involved in determining cell fate and regulating proliferation, including c-MYC, CYCLIN-D1 and more than 50 others (see http://www.stanford.edu/rnusse/ wntwindow.html for further information). Until now, the stabilization and accumulation of b-catenin in malignant cells has been described as the main oncogenic process that deregulates the Wnt/Wingless signalling pathway. It occurs either through activating mutations in b-catenin or by inactivating alterations in genes such as APC or AXIN2 involved in the cytoplasmic degradation of b-catenin. In contrast, transcriptional repression occurs when TCF/LEF factors interact with other nuclear proteins. For example, all these factors have been observed to interact with TLE/GROUCHO corepressors (Brantjes et al., 2001) that also bind both the hypoacetylated N-terminal tail of histone H3 and the human histone deacetylase 1 (HDAC1), suggesting a role for these complexes in forming a specialized, repressive chromatin structure that prevents inappropriate activation of b-catenin/TCF target genes. Such TCF-4 interactions with different partners appear increasingly to be a new key step in regulating Wnt/Wingless signalling at the nuclear level.
We recently characterized the entire genomic structure of human TCF-4 and have reported that it was subject to numerous alternative splicing at its 3 0 end (Duval et al., 2000) . This mechanism is expected to play a role in regulating TCF-4-mediated transcription, as the alternative use of three consecutive exons localized in the 3 0 part of the gene allows the synthesis of numerous TCF-4 isoforms with different C-terminal ends. Among them, those harbouring long C-terminal ends have been proposed to mediate transcriptional repression, as they contain two specific binding domains for CtBP (C-terminal binding protein), an ubiquitous transcriptional repressor (Duval et al., 2000) . Two CtBP factors (e.g. CtBP1 and CtBP2) have so far been described in mammals. Evidence for their interaction with some TCF/LEF factors containing CtBP binding domains (e.g. TCF-3 and TCF-4) has been reported in vitro (Brannon et al., 1999; Valenta et al., 2003) but remains controversial in vivo (Brannon et al., 1999; Hamada and Bienz, 2004) . Briefly, Tcf-3 interaction with CtBP has been demonstrated both in vitro and in vivo in Xenopus, leading to the repression of XTcf-3 transcriptional activity with functional consequences during Xenopus development (Brannon et al., 1999) . In mammals, TCF-4 was demonstrated to interact in vitro with both CtBP1 and CtBP2 by yeast two-hybrid screen, leading to the repression of the expression of the Wnt/ Wingless target Axin2/conductin in CtBP stably transfected human embryonic kidney cells (Valenta et al., 2003) . More recently, Hamada and Bienz confirmed a weak interaction beween TCF-4 and CtBP in vitro by GST pulldown, but failed to confirm such an interaction in cellulo in several cell lines including colorectal cancer cells. Otherwise, CtBP has also been recently demonstrated to directly bind APC in the nucleus, leading to the sequestration of nuclear APC/b-catenin complexes. This was proposed to antagonize TCF-mediated transcription by lowering the availability of free b-catenin for binding to TCF in the nucleus (Hamada and Bienz, 2004) .
Of interest, we recently reported frequent frameshift alterations in an (A)9 coding repeat localized in the last exon of TCF-4 in MSI-H colorectal cancers (Duval et al., 1999) . We showed that the main consequence of such a mutation was the complete absence of TCF-4 isoforms containing CtBP binding domains, and we proposed this event to be oncogenic. In this context, the aim of the present work is to further investigate the role of the controversial interaction between CtBP and TCF-4 in several cell lines including colorectal cancer cells. It is based on alternative methodological approaches, as compared to those already performed in the literature. They notably include a study of the colocalization of these two proteins by confocal microscopy in different cell lines, taking account of (i) the mutational status of TCF-4 in these tumours and (ii) the complex pattern of expression of this transcription factor in these cancers. Our results show a partial colocalization between CtBP and TCF-4 in cellulo that depends on the presence of some TCF-4 isoforms containing CtBP binding sites, as expected. They also show that CtBP is able to repress TCF-4-mediated transcription in vitro. Our data also suggest that the frequent TCF-4 frameshift mutation leads to a complete loss of the ability of this transcription factor to colocalize with CtBP in MSI-H colorectal cancer cells and that in this context, CtBP seems not to be able to repress TCF-4 transcriptional activity. Accordingly, TCF-4 splicing is highlighted as a new key step in regulating TCF-4 transcriptional properties.
Results
CtBP, wild type and mutated TCF-4 are highly expressed in MSI-H colorectal cancers Both LoVo (homozygous A8/A8 TCF-4 mutation) and HCT116 (wild-type TCF-4) cell lines were tested by immunohistochemistry with antibodies directed against either human TCF-4 or CtBP. They showed identical results. CtBP and TCF-4 staining were strong in almost all cells and strictly limited to the nucleus (Figure 1 ). There was no staining of negative controls. A series of 29 MSI-H primary tumours, among which two harboured TCF-4 mutations, spotted on a tissue array showed an identical TCF-4 expression pattern (Figure 2 ).
Evidence for partial colocalization of nuclear CtBP with TCF-4 in colorectal cancer cells and for a loss of such a colocalization in MSI-H cells harbouring the frequent TCF-4 frameshift mutation LoVo, CO115 and HCT116 cell lines were tested by immunofluorescence with antibodies directed against TCF-4 and CtBP. A partial colocalization of these two proteins was observed in CO115 (wild-type TCF-4) and HCT116 (wild-type TCF-4) cell lines ( Figure 3a) and confirmed by spectral analysis using confocal microscopy (Figure 3b ), whereas in Lovo cells (homozygously mutated on TCF-4), it seems that there was no colocalization of the two proteins (Figure 3a ). This was confirmed by further immunofluorescence experiments performed on HCT116 cells transfected with CtBP and either pTCF-4(A)9 encoding for a wild-type TCF-4 isoform containing CtBP binding domains or pTCF-4(A)8 encoding for a mutated TCF-4 isoform lacking CtBP binding domains. In cells transfected with CtBP and pTCF-4(A)9, colocalization of these two proteins was highly enhanced in some parts of the nucleus (Figure 4a ). In cells transfected with CtBP and pTCF-4(A)8, no colocalization of the corresponding proteins was observed ( Figure 4b ). Taken together, these results strongly suggest a colocalization between CtBP and TCF-4 in cellulo that directly depends on the nature of TCF-4 isoforms. They also suggest that the frequent TCF-4 (A)8 frameshift mutation in MSI-H colorectal cancers would lead to a complete loss of TCF-4 ability to interact with this corepressor.
CtBP represses the transcriptional activity of wild-type TCF-4 but not mutant related isoforms in the presence of b-catenin in transfected 293T embryonic kidney cells 293T cells were first transiently transfected with TOP or FOPFLASH and with increasing amounts of pD45 bcatenin and wild-type pTCF-4(A)9 or mutant pTCF-4(A)8 in order to determine the optimal amounts that result in maximum transactivation of the TCF (FLASH) reporter (data not shown). As already reported (Ruckert et al., 2002) , no significant difference was observed in 'FLASH' values obtained with either pTCF-4(A)9 or pTCF-4(A)8. Using the optimal values for pD45 bcatenin (50 ng) and pTCF-4 (A)8 (10 ng) or pTCF-4 (A)9 (10 ng), we added increasing amounts of the expression vector pCtBP (i.e. CtBP ¼ 0, 200, 400 or 600 ng) to the transfection mix. A significant higher expression rate of mCtBP1 mRNA was found in 293T cells transfected with pCtBP as compared to those transfected with the empty vector (e.g. with a ratio of 3, 5 and 7.5 at 200, 400 and 600 ng respectively), confirming the efficiency of the transfection step ( Figure 5 CtBP interacts with some TCF-4 isoforms P Cuilliere-Dartigues et al TOPFLASH (wild type)/FOPFLASH (mutant) ratio (RCtBP) in the presence of CtBP at different concentrations divided by the same TOPFLASH/FOPFLASH ratio in the absence of CtBP. A significant decrease in medium RCtBP values was observed with pTCF-4(A)9 (P ¼ 0.04, Student's t-test comparing medium RCtBP ratio at CtBP ¼ 0 or 600 ng) but not with pTCF-4(A)8 ( Figure 5 ). These results suggest that CtBP acts as a functional repressor of b-catenin/TCF-4 activity and that the frequent TCF-4(A)8 frameshift mutation prevents this repressor effect.
The CtBP repressor effect on TCF-4 transcriptional activity is modified according to TCF-4 mutational status in MSI-H colorectal cancer cells Three MSI-H colorectal cell lines (HCT116, LoVo, CO115), whose status for TCF-4, b-catenin, AXIN2 and APC mutations was known (Gayet et al., 2001) , were transiently transfected with the FLASH firefly luciferase TCF reporter plasmids. Different high TOPFLASH/ FOPFLASH ratio values were observed in each case, demonstrating a high TCF-4 transcriptional activity in these three malignant cancer cell lines. When pCtBP was added to the transfection mix (CtBP ¼ 0, 200 or 600 ng), a significant decrease in b-catenin/TCF-4 activity was observed in CO115 (P ¼ 1.5 Â 10 À4 and P ¼ 5.7 Â 10 À8 , Student's t-test when comparing medium TOPFLASH/ FOPFLASH ratio at CtBP ¼ 0 and 200 ng, or 0 and 600 ng, respectively) and HCT116 (P ¼ 3.9 Â 10 À4 and P ¼ 4.3 Â 10 À5 , Student's t-test when comparing medium TOPFLASH/FOPFLASH ratio at CtBP ¼ 0 and 200 ng or CtBP ¼ 0 and 600 ng, respectively) but not in LoVo (P ¼ 0.15 and P ¼ 0.47, Student's t-test when comparing medium TOPFLASH/FOPFLASH ratio at CtBP ¼ 0 and 200 ng or CtBP ¼ 0 and 600 ng, respectively) (see Figure 6 ). These results demonstrate that CtBP acts as a functional repressor of TCF-4 transcriptional activity in some malignant MSI-H colorectal cells (Figure 6 ). Accordingly, the fact that CtBP was not able to repress TCF-4-mediated transcription in LoVo cells, as compared to Co115 and HCT116, would be related to the presence of homozygous TCF-4 frameshift mutation in this cell line.
The endogenous expression of four genes known to be regulated by the Wnt/Wingless signalling pathway was then measured in HCT116, CO115 and LoVo cells transfected with murine pCtBP (mCtBP1). As expected, high levels of TCF-4 and b-catenin mRNA expression were found in the three cell lines (data not shown). On the contrary, no differences were observed when comparing the expression levels of C-MYC, C-FOS, AXIN2 and PPARD in cells transfected with either pCtBP or the empty vector, suggesting no significant effect of CtBP on the expression of these target genes for Wnt/Wingless signalling (data not shown).
Discussion
In a previous study, we determined the entire genomic structure of human TCF-4 and performed an extensive analysis of its transcriptional expression in colorectal cancer cell lines (Duval et al., 2000) . This allowed us to show the existence of numerous alternative splicing events that affected three consecutive exons localized at the 3 0 end. Accordingly, we reported that similar to other TCF/LEF factors, wild-type TCF-4 expression was complex and that many different TCF-4 isoforms differing in their respective C-terminal ends were synthesized in colorectal cancer cells. The most remarkable difference between these different isoforms is that some of them, called long (L) isoforms, contain CtBP interacts with some TCF-4 isoforms P Cuilliere-Dartigues et al
CtBP binding domains, and some do not. We suggested that this mechanism could be of functional significance for regulating TCF-4 transcriptional activity. TCF-4 mutation is frequent (Duval et al., 1999) in colorectal cancers with defective mismatch repair (MSI-H type) (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) . The consequence of this mutation is a frameshift leading to the exclusive synthesis of TCF-4 isoforms lacking CtBP binding sites. Both mutant and wild-type TCF-4 proteins were observed here using immunohistochemistry to be highly expressed, and to show the same nuclear localization in colorectal cancer cell lines and primary tumours. Until now, CtBP interaction with TCF/LEF factors has been reported in vitro with TCF-4 in humans (Valenta et al., 2003; Hamada and Bienz, 2004) and both in vitro and in vivo with TCF-3 in Xenopus (Brannon et al., 1999) , the only two TCF/LEF factors containing CtBP binding domains in their 3 0 ends. The CtBP/TCF-4 interaction remains controversial in cellulo in humans (Hamada and Bienz, 2004) . The CtBP/TCF-4 interaction reported here in human cells is weak and seems to involve only a minor fraction of the numerous CtBP interacts with some TCF-4 isoforms P Cuilliere-Dartigues et al TCF-4 spliced isoforms in the nucleus (Figure 3) . Such an interaction was confirmed however by transfection experiments using plasmids encoding for CtBP and for a TCF-4 isoform containing CtBP binding domains (Figure 4 ). Compared to wild-type TCF-4, mutated TCF-4 never colocalized with CtBP in the nucleus. The plasmids pTCF-4 (A)9 or pTCF-4 (A)8 used in this study encode TCF4 unique isoforms, with and without CtBP binding domains, respectively (Figure 4 ). Although imperfect, by reflecting the situation in cells with the complete set of TCF4 isoforms, all these results argue for a weak but real colocalization of CtBP with TCF-4 in the nucleus, and also suggest an inability of mutant TCF-4 protein to colocalize with CtBP.
Using an in vitro luciferase reporter kit system in 293T cells (wild-type TCF-4), CtBP was found to repress TCF-4 transcriptional activity in the presence of nuclear b-catenin. It was also found to significantly repress TCF-4 transcriptional activity in some colorectal cancer cells, for example, HCT116 and CO115 (wildtype TCF-4). Conversely, it did not repress the endogenous expression of four genes known to be highly expressed following b-catenin/TCF-4 signalling in these cell lines. This should be explained by the fact that we only developed here transient but not stable transfection experiments using a pCtBP expression vector. Notably, CtBP was found to be unable to modulate the endogeneous expression of AXIN2, in contrast to a recent report by Valenta et al. (2003) . These authors used stably transfected 293-EGFP-CtBP/ Dox cells that (i) express high levels of TCF-4 mRNA and produce predominantly the longer variant, that is the TCF-4E form of TCF-4 protein, which contains CtBP binding motifs, and (ii) contain an integrated CtBP1 transgene whose expression is highly inducible upon doxycyclin treatment. Accordingly, expression studies using microarray approaches in stably transfected cells with CtBP should now be performed to conclude in this field. They would allow to determine a series of genes whose expression would be directly modulated in a CtBP-dependant manner in these tumours. CtBP interacts with some TCF-4 isoforms P Cuilliere-Dartigues et al
Despite the discrepancy, the current results and those of Valenta et al. suggest a role for CtBP in repressing Wnt/Wingless signalling. Such an impact of CtBP on Wnt/Wingless signalling could result from its binding with some TCF-4 isoforms, as suggested here, but also from its binding with a 15R motif on the APC protein, as recently proposed (Hamada and Bienz, 2004) . As with other colorectal cancer cell lines, HCT116, LoVo and CO115 are characterized by different but high TCF-4 transcriptional activities owing to simultaneous mutations affecting APC, b-catenin, AXIN2 and/or TCF-4 (Gayet et al., 2001) . In both HCT116 and CO115 cells (wild type APC and wild type TCF-4), CtBP is able to significantly repress TCF-4 transcriptional activity, whereas it has no effect on the overall activity of this transcription factor in LoVo (bi-allelic frameshift mutations on both APC and TCF-4). In most of colorectal cancer cell lines (including LoVo) with mutations in the APC gene, these alterations are localized in the 15th exon, which is the last one. It is thus not expected that the so-called nonsense-mediated decay (NMD) system would degrade the corresponding mutated mRNA (Holbrook et al., 2004) . Moreover, most of these alterations (with the exception of Colo320 APC mutation) are localized downstream of the 15R CtBP binding motif of the APC protein, so that this function should be conserved, as already suggested by in vitro studies (Hamada and Bienz, 2004) . In this context, it is thus unlikely that the loss of interaction between APC and CtBP would play an important role during colorectal carcinogenesis. In the particular case of LoVo, we suggest rather that CtBP has no effect on TCF-4 transcriptional activity because it is no longer able to bind TCF-4, suggesting a real impact of this alteration during MSI-H tumour progression. In transfected 293T cells, the fact that a CtBP repressor effect was only obtained in the presence of wild-type but not mutated isoform of TCF-4 lacking CtBP binding domains also argues for a functional role of the TCF-4/CtBP interaction in regulating TCF-4-mediated signalling.
We have provided data that support an additional role for CtBP in regulating the TCF-4 transcriptional activity upon its association with some alternatively spliced TCF-4 mRNA-encoded isoforms. Accordingly, the putative role for CtBP in regulating Wnt/Wingless signalling is highlighted. Further experiments using siRNA against CtBP and/or APC in a series of colorectal cancer cell lines would be now of interest to further characterize the respective role of the interaction of CtBP with either APC and TCF-4 in regulating this pathway, and the putative tumour suppressor role that it is expected to play according to this two-hits mechanism. The functional significance of its partial colocalization with TCF-4 also highlights the importance of TCF-4 splicing in regulating TCF-4 transcriptional properties. In this model, CtBP can be thought of as a factor that modifies TCF-4-mediated signalling in a subtle manner, leading to modification in the expression of as yet unknown downstream target genes in the Wnt/ Wingless pathway. This provides evidence for a functional effect of the frequent TCF-4 frameshift mutation observed in mismatch repair-deficient colorectal cancers. In these tumours, TCF-4 represents the first target gene whose alteration acts as an activating rather than an inactivating event, in contrast to the frameshift mutations that affect tumour suppressor genes such as TGFRII, BAX, CASPASE-5, IGFIIR and others (Duval and Hamelin, 2002) . In vivo approaches using transgenic mice for the TCF-4 frameshift mutation would be now of interest to understand the oncogenic role of such a mutational event in colorectal carcinogenesis.
Materials and methods

Transfection assays
Human 293 embryonic kidney cells, as well as CO115, LoVo and HCT116 MSI-H colorectal cancer cells, were maintained in DMEM (Life Technologies) containing 10% FCS (Invitrogen SARI, Cergy, Pontoise Cedex, France). As already reported (Duval et al., 2000) , the entire TCF-4 gene coding sequence has been screened for mutations in LoVo (homozygous A8/A8 one base pair deletion in the (A)9 TCF-4 coding repeat), but not in CO115 (wild type) and HCT116 (wild type). HCT116 is also known to harbour heterozygous b-catenin and AXIN2 alterations (Gayet et al., 2001) . LoVo is known to harbour homozygous APC mutation (Gayet et al., 2001) . CO115 is not mutated on these two latter genes. A table indicating the mutational status of TCF-4, b-catenin, APC and AXIN-2 in these cell lines and others is available online (see http://www.cephb.fr/gaccc/). Colorectal cancer cells were transfected in 24 cluster well plates (10 6 cells per well) using Fugene 6 transfection reagent (Roche Diagnostics, Meylan, France) with constant amounts (100 ng) of the firefly luciferase TCF reporter plasmids TOP-FLASH or FOP-FLASH (Upstate Biotechnology, Inc., Lake Placid, NY, USA), together with increasing amounts of expression vector pCtBP, encoding the murine mCtBP1 isoform (murine mCtBP1 is 93% similar to human CtBP1 at the peptide level). TOP-FLASH and FOP-FLASH promoters contained three copies of the optimal Tcf motif CCTTTGATC, or three copies of the mutant motif CCTTGGCC, upstream of a minimal c-Fos promoter driving luciferase expression, respectively. In other experiments, TOP-FLASH or FOP-FLASH vectors were co-transfected in 293T cells with constant amounts of the expression vectors pD45bcatenin (50 ng), and pTCF-4(A)9 (10 ng) or pTCF-4(A)8 (10 ng) (gifts from Andreas Jung and Bert Vogelstein). pcDNA3.1 f(À) (Invitrogen), an empty vector, was added in each experiment to make up DNA to a constant amount (800 ng). All transfections were carried out at least six times. Luciferase values were measured after overnight incubation, using the dual light kit (Promega) according to the manufacturer's instructions. Transactivation FLASH values were calculated in each case by the ratio TOPFLASH/FOPFLASH (the TCF and control reporters, respectively).
Quantitative RT-PCR analysis in transfected cell lines 293T, HCT116, CO115 and LoVo transfected cells were collected after overnight, 24, 48 and 72 h incubations. Total RNA was extracted from each cell line using the RNEasy extraction kit (Qiagen S.A., Courtaboeuf Cedex, France) and cDNA was synthesized using the high capacity cDNA archive kit (Applied Biosystems, Foster City, CA, USA). For quantitative RT-PCR experiments, relative expression values were obtained as described (El Bchiri et al., 2005) using the 18S ubiquitous RNA as an endogenous reference. Primers and internal probes for 18S, TCF-4, b-catenin and four target genes (e.g. C-MYC, AXIN2, PPARD, C-FOS) were those proposed on demand by Applied Biosystems (TaqMan gene expression assays on demand). For each set of primers, a no-template control and a no-reverse transcriptase control (reverse transcriptase-negative) assays produced negligible signals (usually C t >35) and were used to confirm the absence of primer-dimer formation and genomic DNA contamination. PCR reactions were performed in triplicate as described (El Bchiri et al., 2005) . In each case, relative expression values were compared between cells transfected with either pCtBP or the empty vector.
Immunohistochemical staining of colorectal cancer cell lines and primary tumours on tissue microarrays Immunohistochemistry was performed on cell lines and primary colorectal cancers. The cells were fixed in 10% formalin for 24 h and centrifuged at 1500 r.p.m. for 5 min (Cytospin 3, Shandon, Pittsburgh, PA, USA). The pellets were embedded in paraffin. Sections (5 mm) of blocks were cut onto silane-treated Super Frost slides (CML, Nemours, France) and allowed to dry at 371C overnight. For primary colorectal cancers, 29 MSI-H cases were studied on tissue microarrays as previously described (Jourdan et al., 2003) . These tumours had previously been screened for TCF-4 mutations. Slides were deparaffinized in xylene and rehydrated in pure ethanol. Endogenous peroxidase was blocked using 3% hydrogen peroxide in methanol for 30 min. For antigen retrieval, sections were placed in a microwave oven in citrate buffer (pH 6.0) for 15 min at 750 W followed by a further 15 min at 150 W. All slides were processed using an automatic immunostainer (Optimax Plus 1.5, Biogenex, San Ramon, USA) with a supersensitive biotin-streptavidin-peroxidase technique (Super Sensitive Detection Kit, Biogenex). Mouse anti-human monoclonal antibody to human TCF-4 (residues 31-331) (dilution 1:100, clone 6H5-3; Upstate Biotechnology, Lake Placid, NY, USA) was used on cell lines and primary tumours, and rabbit polyclonal antibody to recombinant protein corresponding to amino acids 1-440 representing full length of human CtBP1 (dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used on cell lines only. Slides were developed with amino-ethyl-carbazole (Vector, Burlingame, CA, USA) as the chromogen. The sections were washed in running tap water and lightly counterstained in Mayer's hematoxylin. For negative controls, non-immune mouse IgG was used as a substitute for TCF-4 or CtBP antibodies. The intensity of staining was scored semiquantitatively (0: no staining; þ : mild; þ þ : moderate; þ þ þ : strong). Two observers evaluated the slides independently. Discordant cases were reviewed for consensus.
Study of TCF-4 and CtBP subcellular localization by immunofluorescence using confocal microscopy MSI-H cancer cells (e.g. HCT116, CO115 and LoVo) were plated in Nalge Nunc slide chambers, fixed with 4% formaldehyde and blocked with PBS containing 5% goat serum. The same primary rabbit (CtBP) and mouse (TCF-4) monoclonal antibodies as described above were used at a concentration of 2.5 mg/ml in PBS buffer containing 1% BSA and 0.2% Tween 20. Donkey anti-rabbit and anti-mouse IgG, FITC or Cy3 conjugated, 1:200 (Pierce Biotechnology Inc., Rockford, IL, USA), diluted in the buffer, were used as secondary antibodies. TCSSP confocal microscope (Leica) was used to assess the subcellular localization of the TCF-4 and CtBP proteins. Each study, performed in duplicate, was repeated at least once. In other experiments, the same approach was used to look for putative colocalization of CtBP with either the wild-type or mutated TCF-4 isoforms in HCT116 cells transfected with pCtBP and pTCF-4(A)9 or pTCF-4(A)8 respectively, as described above.
